Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1539-0829
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease ; volume:22 ; number:1 ; day:3 ; month:2 ; year:2022 ; pages:39-52 ; date:1.2022
Current diabetes reports ; 22, Heft 1 (3.2.2022), 39-52, 1.2022
- Creator
-
Bailey, Clifford J.
Day, Caroline
Bellary, Srikanth
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11892-021-01442-z
- URN
-
urn:nbn:de:101:1-2022052907213936230325
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bailey, Clifford J.
- Day, Caroline
- Bellary, Srikanth
- SpringerLink (Online service)
Other Objects (12)
Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease
Early Initiation of SGLT2 Inhibitors in Acute Heart Failure: a Focus on Diuresis and Renal Protection
Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
Angiotensin Receptor-Neprilysin Inhibitor for Chronic Kidney Disease: Strategies for Renal Protection
Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review
Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
Direct cardiac effects of SGLT2 inhibitors
Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease
Early Initiation of SGLT2 Inhibitors in Acute Heart Failure: a Focus on Diuresis and Renal Protection
Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
Angiotensin Receptor-Neprilysin Inhibitor for Chronic Kidney Disease: Strategies for Renal Protection
Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review
Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
Direct cardiac effects of SGLT2 inhibitors
Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease
Early Initiation of SGLT2 Inhibitors in Acute Heart Failure: a Focus on Diuresis and Renal Protection
Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
Angiotensin Receptor-Neprilysin Inhibitor for Chronic Kidney Disease: Strategies for Renal Protection
Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review
Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape